Dennis Bittner, PhD | Authors

May 13, 2015

The US Food and Drug Administration (FDA) released new guidance on the use of alternative endpoints, in addition to overall survival (OS), for clinical trials of non–small cell lung cancer (NSCLC) therapies.

March 24, 2015

Following recent approvals by the US Food and Drug Administration (FDA) of pembrolizumab and nivolumab, numerous programs to develop and expand use of immunotherapies have ensued.

February 25, 2015

The definition of liquid biopsy has expanded to include the collection of cfDNA, along with various species of cell-free RNA and exosomes, all of which are capable of providing information on the disease status of cancer patients.

February 11, 2015

A panel of expert clinical investigators discussed details of several treatments and a dozen patient cases involving gastric, colorectal, and pancreatic cancer at a satellite meeting of the 2015 ASCO GI Cancers Symposium.

February 06, 2015

Comparable test results were shown with both urine and plasma molecular assays in a blinded, retrospective study.

February 06, 2015

A post-hoc analysis of the CORRECT trial showed that patients with mCRC who had PFS >4 months, experienced AEs at rates broadly similar to those in the overall trial population.